SKB575 vs Sunakiment

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Asthma

Shared mechanism: TSLP · full Asthma pipeline

SKB575

Developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners

Phase 1 in Asthmabispecific antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2028 · NCT07732023 (registry estimate)

No aligned efficacy figure on record for this race.

Sunakiment

Developed by AstraZeneca and partners

Phase 2 in Asthmaantibody fragment
Partial signal

NCT06529419 · Phase 2 · completed

The study randomized 537 participants across three AZD8630 dose groups and placebo, with participants, care providers, investigators, and outcome assessors quadruple-blinded. Its primary endpoint was a clinical exacerbation-related measure, but the primary comparison cannot yet be judged because results have not been reported.

Reported efficacy

Part A and Part B: Number of participants with adverse events (Until Follow-up (FU) Visit/Early Termination (ET) Visit (Part A: 7-day post-dose for SAD; 10-day post-last dose for MAD) and Part B: Until FU Visit/ET Visit (10-day post-last dose)); Part A (IV cohort): Time to reach maximum observed concentration (tmax) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Time of last observed quantifiable concentration (tlast) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Maximum observed serum (peak) drug concentration (Cmax) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Partial area under the serum concentration-time curve from 0 to time 24 hours post-dose [AUC(0-24)] of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Area under the serum concentration curve from zero to the last quantifiable concentration (AUClast) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Area under serum concentration-time curve from zero to infinity (AUCinf) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Terminal rate constant (λz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Mean residence time of the unchanged drug in the systemic circulation (MRTinf) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Total body clearance of drug from serum after IV administration (CL) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV cohort): Volume of distribution at steady state (Vss) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV Cohort): Volume of distribution of drug from serum after IV administration (Vz) of AZD8630 (Pre-dose and Post-dose on Days 1 to 4 and Follow-up Visit/ET Visit (7-day post-dose)); Part A (IV Cohort): Number of participants with adverse events (Until Follow-up (FU) Visit/Early Termination (ET) Visit (7-day post-dose)): Primary outcome, adverse events in Part A (healthy adults) and Part B (asthma): acceptable safety profile, low incidence of treatment-induced antidrug antibodies (part A n=1; part B n=2); safety outcome, no formal efficacy test. The other registered primaries are pharmacokinetic. Secondary outcome, FeNO change vs placebo at day 28 in Part B: 23% reduction with 8 mg (P=.037). (not_applicable)

Result source: NCT05110976

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointSKB575Sunakiment
Severe exacerbations, annualised rate—Not reported—Not reported
Trough FEV1, change—Not reported—Not reported
ACQ-5, change—Not reported—Not reported
OCS dose reduction—Not reported—Not reported

Severe exacerbations, annualised rate

SKB575
—Not reported
Sunakiment
—Not reported

Trough FEV1, change

SKB575
—Not reported
Sunakiment
—Not reported

ACQ-5, change

SKB575
—Not reported
Sunakiment
—Not reported

OCS dose reduction

SKB575
—Not reported
Sunakiment
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SKB575: no structured comparison results are available for Asthma.

Sunakiment: no structured comparison results are available for Asthma.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: SKB575's landscape · Sunakiment's landscape